登录

前列腺癌症的无进展生存终点:我们真的在进步吗

Progression-free survival end points in prostate cancer: are we truly making progress

Nature 2024-06-17 19:31 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear..

最近,仅基于无进展生存益处,前列腺癌的几种治疗策略已获得监管部门的批准,这是前列腺癌治疗方法治疗发展的相对变化。以前,总体生存是批准的要求。这种方法是否对患者有保证或有益尚不清楚。。

Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

This is a preview of subscription content, access via your institution

这是订阅内容的预览,可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on Springer LinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+,我们最有价值的在线订阅24,99欧元/30天,随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springer link上购买即时访问完整文章PDFBuy now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项:

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesSayegh, N., Swami, U. & Agarwal, N. Recent advances in the management of metastatic prostate cancer. JCO Oncol. Pract. 18, 45–55 (2022).Article

ReferenceSayegh,N.,Swami,U。和Agarwal,N。转移性前列腺癌管理的最新进展。。实践。18,45-55(2022)。文章

PubMed

PubMed

Google Scholar

谷歌学者

Kelly, W. K. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J. Clin. Oncol.

Kelly,W.K.等人,一项随机、双盲、安慰剂对照的III期临床试验,比较多西紫杉醇、泼尼松和安慰剂与多西紫杉醇、泼尼松和贝伐单抗治疗转移性去势抵抗性前列腺癌(mCRPC)患者的生存结果:CALGB 90401。J、 临床。Oncol公司。

28 (Suppl. 18), LBA5411 (2010)..

28(补充18),LBA5411(2010)。

Google Scholar

谷歌学者

Kelly, W. K. et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30, 1534–1540 (2012).Article

Kelly,W.K.等人。比较多西紫杉醇和泼尼松联合或不联合贝伐单抗治疗转移性去势抵抗性前列腺癌男性的随机、双盲、安慰剂对照III期临床试验:CALGB 90401。J、 临床。Oncol公司。301534-1540(2012)。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Agarwal, N. et al. CONTACT-02: phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 42 (Suppl. 4), 18 (2024).

Agarwal,N。等人,CONTACT-02:cabozantinib(C)加atezolizumab(A)与第二种新型激素治疗(NHT)治疗转移性去势抵抗性前列腺癌(mCRPC)患者的3期研究。J、 临床。Oncol公司。42(补充4),18(2024)。

Google Scholar

谷歌学者

de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381, 2506–2518 (2019).Article

de Wit,R.等。卡巴齐紫杉醇与阿比特龙或恩扎鲁胺治疗转移性前列腺癌症。N.Engl。《医学杂志》3812506-2518(2019)。文章

PubMed

PubMed

Google Scholar

谷歌学者

Smith, M. et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J. Clin. Oncol. 34, 3005–3013 (2016).Article

Smith,M.等人。卡博替尼在先前治疗的转移性去势抵抗性前列腺癌中的III期研究:COMET-1。J、 临床。Oncol公司。343005-3013(2016)。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Sternberg, C. N. et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 27, 5431–5438 (2009).Article

Sternberg,C.N.等人。泼尼松和satraplatin或安慰剂治疗先前化疗后进展的去势难治性前列腺癌患者的多国双盲III期研究:SPARC试验。J、 临床。Oncol公司。275431-5438(2009)。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291–303 (2023).Article

阿加瓦尔(Agarwal,N.)等人(Talazoparib plus enzalutamide)治疗一线转移性去势抵抗性前列腺癌(TALAPRO-2)患者:一项随机、安慰剂对照的3期临床试验。柳叶刀402291-303(2023)。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Chi, K. N. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann. Oncol. 34, 772–782 (2023).Article .

Chi,K.N.等人,《尼拉帕利联合醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌和同源重组修复基因改变的患者:随机III期MARIGNET试验的第二次中期分析》。安科。34772-782(2023)。文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1094–1108 (2023).Article

Saad,F。等人。奥拉帕尼联合阿比特龙与安慰剂联合阿比特龙治疗转移性去势抵抗性前列腺癌(PROpel):一项随机,双盲,3期临床试验的最终预先确定的总体生存结果。柳叶刀Oncol。241094-1108(2023)。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Madan, R. A., Karzai, F., VanderWeele, D. J., Cheng, H. H. & de Bono, J. S. Poly(ADP-ribose) polymerase inhibitor combinations in first-line metastatic castration-resistant prostate cancer: increasing toxicity with unclear benefits. J. Clin. Oncol. 41, 5501–5504 (2023).Article

Madan,R.A.,Karzai,F.,VanderWeele,D.J.,Cheng,H.H。&de Bono,J.S。聚(ADP-核糖)聚合酶抑制剂组合在一线转移性去势抵抗性前列腺癌中:增加毒性但益处不明确。J、 临床。Oncol公司。415501-5504(2023)。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).Article

Sartor,O.等人,Lutetium-177-PSMA-617用于转移性去势抵抗性前列腺癌。N、 英语。J、 医学3851091-1103(2021)。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Sartor, O. et al. Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) [abstract LBA13]. Ann. Oncol. 34 (Suppl. 2), 1254–1335 (2023).

Sartor,O.等人[177Lu]Lu-PSMA-617在未接受紫杉烷治疗的转移性去势抵抗性前列腺癌(PSMAfore)患者中的III期临床试验[摘要LBA13]。安科。34(补充2),1254-1335(2023)。

Google Scholar

谷歌学者

Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).Article

Tannock,I.F.等人,多西紫杉醇联合泼尼松或米托蒽醌联合泼尼松治疗晚期前列腺癌。N、 英语。J、 医学3511502-1512(2004)。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Hussain, M. et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383, 2345–2357 (2020).Article

Hussain,M.等人。奥拉帕尼在转移性去势抵抗性前列腺癌中的存活率。N、 英语。J、 医学3832345-2357(2020)。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USARavi A. MadanSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USAEdwin M. PosadasDepartment of Medicine, Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USARichard J.

LeeAuthorsRavi A. MadanView author publicationsYou can also search for this author in.

LeeAuthorsRavi A.MadanView作者出版物您也可以在中搜索此作者。

PubMed Google ScholarEdwin M. PosadasView author publicationsYou can also search for this author in

PubMed Google ScholarEdwin M.PosadasView作者出版物您也可以在

PubMed Google ScholarRichard J. LeeView author publicationsYou can also search for this author in

PubMed Google ScholarRichard J.LeeView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Ravi A. Madan.Ethics declarations

拉维·A·马丹。道德宣言

Competing interests

相互竞争的利益

The authors declare no competing interests.

作者声明没有利益冲突。

Rights and permissionsReprints and permissionsAbout this articleCite this articleMadan, R.A., Posadas, E.M. & Lee, R.J. Progression-free survival end points in prostate cancer: are we truly making progress.

权利和许可打印和许可本文引用本文Madan,R.A.,Posadas,E.M。&Lee,R.J。前列腺癌的无进展生存终点:我们真的取得了进展吗。

Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00902-xDownload citationPublished: 17 June 2024DOI: https://doi.org/10.1038/s41585-024-00902-xShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Urol(2024年)。https://doi.org/10.1038/s41585-024-00902-xDownload引文发布日期:2024年6月17日OI:https://doi.org/10.1038/s41585-024-00902-xShare本文与您共享以下链接的任何人都可以阅读此内容:获取可共享链接对不起,本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供

推荐阅读

120多名医生参加了关于介入骨科和非手术治疗进展的会议

Medgate Today 2024-07-13 20:52

北京大学第三医院4个牵头项目荣获2023年北京医学科技奖

北京大学医学部 2024-07-13 20:23

与NeoRAS野生型转移性癌症相关的临床特征——SCRUM-Japan GOZILA亚研究

Nature 2024-07-13 19:13

Nature

905篇

最近内容 查看更多

与NeoRAS野生型转移性癌症相关的临床特征——SCRUM-Japan GOZILA亚研究

5 小时后

迈向个人健康数据国家研究数据基础设施的互操作性格局

3 小时后

神经丝轻链循环水平作为缺血性卒中后梗死和白质高信号量的生物标志物

1 小时后

产业链接查看更多